PharmAust has received the key ethics approval from the New South Wales Department of Primary Industry to proceed with the Phase II clinical trials for its anti-cancer drug Monepantel in dogs with B-cell lymphoma, the most common form of canine cancer. The company will begin recruitment of dogs for the Phase II trial after it takes delivery of the tablets from the US in August or September.
15/07/2019 - 11:12
PharmAust secures key ethics nod for Phase II cancer trials
By Matt Birney
15/07/2019 - 11:12
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
23 Jul 2021
PharmAust looks to patent anti-cancer drug
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX